Strs Ohio Makes New $35.65 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Strs Ohio has acquired 315,000 shares of Zimmer Biomet Holdings, valued at approximately $35.65 million, representing 0.16% of the company's stock.
• Zimmer Biomet's recent earnings report showed an EPS of $2.07, exceeding analyst estimates, and a year-over-year revenue increase of 7.0%.
• The company has announced a quarterly dividend of $0.24 per share, with a payment date set for October 31, reflecting a modest annual yield of 0.9%.

Strs Ohio bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 315,000 shares of the medical equipment provider's stock, valued at approximately $35,652,000. Strs Ohio owned about 0.16% of Zimmer Biomet as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $204,000. Focus Partners Wealth raised its position in shares of Zimmer Biomet by 16.2% during the 4th quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider's stock worth $1,760,000 after purchasing an additional 2,303 shares during the period. OMERS ADMINISTRATION Corp raised its position in shares of Zimmer Biomet by 19.9% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 8,684 shares of the medical equipment provider's stock worth $917,000 after purchasing an additional 1,443 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $648,000. Finally, Nuveen Asset Management LLC raised its position in shares of Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after purchasing an additional 913,310 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded down $1.11 during trading on Friday, hitting $103.15. The stock had a trading volume of 883,462 shares, compared to its average volume of 1,177,293. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market cap of $20.43 billion, a P/E ratio of 25.10, a PEG ratio of 2.37 and a beta of 0.68. The business has a fifty day moving average of $99.46 and a two-hundred day moving average of $99.55. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research reports. Royal Bank Of Canada increased their price target on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Evercore ISI reduced their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Raymond James Financial boosted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, UBS Group boosted their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $111.00.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.